118 related articles for article (PubMed ID: 28217196)
1. Effect of Ivacaftor on Objective and Subjective Measures of Cough in Patients with Cystic Fibrosis.
Faruqi S; Shiferaw D; Morice AH
Open Respir Med J; 2016; 10():105-108. PubMed ID: 28217196
[TBL] [Abstract][Full Text] [Related]
2. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
3. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).
McKone EF; Borowitz D; Drevinek P; Griese M; Konstan MW; Wainwright C; Ratjen F; Sermet-Gaudelus I; Plant B; Munck A; Jiang Y; Gilmartin G; Davies JC;
Lancet Respir Med; 2014 Nov; 2(11):902-910. PubMed ID: 25311995
[TBL] [Abstract][Full Text] [Related]
5. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
[TBL] [Abstract][Full Text] [Related]
6. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
8. [Validation of the Chinese version of Hull airway reflux questionnaire and its application in the evaluation of chronic cough].
Huang Y; Yu L; Xu XH; Chen Q; Lyu HJ; Jin XY; Qiu ZM
Zhonghua Jie He He Hu Xi Za Zhi; 2016 May; 39(5):355-61. PubMed ID: 27180589
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
10. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
11. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
13. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
14. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
[TBL] [Abstract][Full Text] [Related]
15. Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.
Taylor-Cousar J; Niknian M; Gilmartin G; Pilewski JM;
J Cyst Fibros; 2016 Jan; 15(1):116-22. PubMed ID: 25682022
[TBL] [Abstract][Full Text] [Related]
16. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
[TBL] [Abstract][Full Text] [Related]
17. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
[TBL] [Abstract][Full Text] [Related]
18. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
[TBL] [Abstract][Full Text] [Related]
19. IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation.
van de Peppel IP; Doktorova M; Berkers G; de Jonge HR; Houwen RHJ; Verkade HJ; Jonker JW; Bodewes FAJA
J Cyst Fibros; 2019 Mar; 18(2):286-293. PubMed ID: 30279125
[TBL] [Abstract][Full Text] [Related]
20. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Rosenfeld M; Wainwright CE; Higgins M; Wang LT; McKee C; Campbell D; Tian S; Schneider J; Cunningham S; Davies JC;
Lancet Respir Med; 2018 Jul; 6(7):545-553. PubMed ID: 29886024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]